Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease

Neurobiology of Disease

Volumn 56, Issue , 2013, Pages 47-58

  Febbraro, Fabia ^a   Sahin, Gurdal ^b   Farran, Aina ^a   Soares, Sofia ^a   Jensen, Poul H ^a   Kirik, Deniz ^b   Romero Ramos, Marina ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Adeno associated virus; Alpha synuclein; Serine phosphorylation; Striatum

Indexed keywords

ALANINE; ALPHA SYNUCLEIN; ASPARTIC ACID; MUTANT PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; GENE OVEREXPRESSION; IN VIVO STUDY; MOTOR DYSFUNCTION; MUTATION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SUBSTANTIA NIGRA; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CORPUS STRIATUM; DENSITOMETRY; DEPENDOVIRUS; DOPAMINE; FEMALE; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MOVEMENT DISORDERS; MUTATION; PARKINSON DISEASE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SERINE; TRANSGENES;

EID: 84877352565     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.03.014     Document Type: Article

References (52)

1. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., Barbour R., Huang J., Kling K., Lee M., Diep L., Keim P.S., Shen X., Chataway T., Schlossmacher M.G., Seubert P., Schenk D., Sinha S., Gai W.P., Chilcote T.J. Phosphorylation of Ser 129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281:29739-29752.
2. Apetri M.M., Maiti N.C., Zagorski M.G., Carey P.R., Anderson V.E. Secondary structure of alpha-synuclein oligomers: characterization by Raman and atomic force microscopy. J. Mol. Biol. 2006, 355:63-71.
3. Azeredo da Silveira S., Schneider B.L., Cifuentes-Diaz C., Sage D., Abbas-Terki T., Iwatsubo T., Unser M., Aebischer P. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 2009, 18:872-887.
4. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., Trojanowski J.Q., Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152:879-884.
5. Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M., Sudhof T.C. {alpha}-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
6. Chen L., Feany M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 2005, 8:657-663.
7. Chen L., Periquet M., Wang X., Negro A., McLean P.J., Hyman B.T., Feany M.B. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Invest. 2009, 119:3257-3265.
8. Colla E., Coune P., Liu Y., Pletnikova O., Troncoso J.C., Iwatsubo T., Schneider B.L., Lee M.K. Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J. Neurosci. 2012, 32:3306-3320.
9. Eriksen J.L., Przedborski S., Petrucelli L. Gene dosage and pathogenesis of Parkinson's disease. Trends Mol. Med. 2005, 11:91-96.
10. Eslamboli A., Romero-Ramos M., Burger C., Bjorklund T., Muzyczka N., Mandel R.J., Baker H., Ridley R.M., Kirik D. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007, 130:799-815.
11. Fiske M., Valtierra S., Solvang K., Zorniak M., White M., Herrera S., Konnikova A., Brezinsky R., Debburman S. Contribution of alanine-76 and serine phosphorylation in alpha-synuclein membrane association and aggregation in yeasts. Park. Dis. 2011, 2011:392180.
12. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
13. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
14. Gorbatyuk O.S., Li S., Sullivan L.F., Chen W., Kondrikova G., Manfredsson F.P., Mandel R.J., Muzyczka N. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:763-768.
15. Gorbatyuk O.S., Li S., Nha Nguyen F., Manfredsson F.P., Kondrikova G., Sullivan L.F., Meyers C., Chen W., Mandel R.J., Muzyczka N. Alpha-synuclein expression in rat substantia nigra suppresses phospholipase D2 toxicity and nigral neurodegeneration. Mol. Ther. 2010, 18:1758-1768.
16. Gundersen H.J., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 1987, 147(Pt 3):229-263.
17. Hirai Y., Fujita S.C., Iwatsubo T., Hasegawa M. Phosphorylated alpha-synuclein in normal mouse brain. FEBS Lett. 2004, 572:227-232.
18. Jensen P.H., Hager H., Nielsen M.S., Hojrup P., Gliemann J., Jakes R. Alpha-synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 1999, 274:25481-25489.
19. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 1998, 152:259-277.
20. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., Bjorklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 2002, 22:2780-2791.
21. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2884-2889.
22. Kragh C.L., Lund L.B., Febbraro F., Hansen H.D., Gai W.P., El-Agnaf O., Richter-Landsberg C., Jensen P.H. {alpha}-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J. Biol. Chem. 2009, 284:10211-10222.
23. Kuwahara T., Tonegawa R., Ito G., Mitani S., Iwatsubo T. Phosphorylation of alpha-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. J. Biol. Chem. 2012, 287:7098-7109.
24. Lee B.R., Kamitani T. Improved immunodetection of endogenous alpha-synuclein. PLoS One 2011, 6:e23939.
25. Lee K.W., Chen W., Junn E., Im J.Y., Grosso H., Sonsalla P.K., Feng X., Ray N., Fernandez J.R., Chao Y., Masliah E., Voronkov M., Braithwaite S.P., Stock J.B., Mouradian M.M. Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. J. Neurosci. 2011, 31:6963-6971.
26. Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., Dawson T.M., Jakala P., Hartmann T., Price D.L., Lee M.K. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2162-2167.
27. Lindersson E., Lundvig D., Petersen C., Madsen P., Nyengaard J.R., Hojrup P., Moos T., Otzen D., Gai W.P., Blumbergs P.C., Jensen P.H. p25alpha stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J. Biol. Chem. 2005, 280:5703-5715.
28. Lo Bianco C., Schneider B.L., Bauer M., Sajadi A., Brice A., Iwatsubo T., Aebischer P. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17510-17515.
29. Marti M.J., Tolosa E., Campdelacreu J. Clinical overview of the synucleinopathies. Mov. Disord. 2003, 18(Suppl. 6):S21-S27.
30. McFarland M.A., Ellis C.E., Markey S.P., Nussbaum R.L. Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol. Cell. Proteomics 2008, 7:2123-2137.
31. McFarland N.R., Fan Z., Xu K., Schwarzschild M.A., Feany M.B., Hyman B.T., McLean P.J. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J. Neuropathol. Exp. Neurol. 2009, 68:515-524.
32. Michell A.W., Tofaris G.K., Gossage H., Tyers P., Spillantini M.G., Barker R.A. The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant. 2007, 16:461-474.
33. Paleologou K.E., Schmid A.W., Rospigliosi C.C., Kim H.Y., Lamberto G.R., Fredenburg R.A., Lansbury P.T., Fernandez C.O., Eliezer D., Zweckstetter M., Lashuel H.A. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem. 2008, 283:16895-16905.
34. Paleologou K.E., Kragh C.L., Mann D.M., Salem S.A., Al-Shami R., Allsop D., Hassan A.H., Jensen P.H., El-Agnaf O.M. Detection of elevated levels of soluble {alpha}-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009, 132:1093-1101.
35. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Academic Press, London.
36. Sanchez-Guajardo V., Febbraro F., Kirik D., Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One 2010, 5:e8784.
37. Sato H., Arawaka S., Hara S., Fukushima S., Koga K., Koyama S., Kato T. Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J. Neurosci. 2011, 31:16884-16894.
38. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
39. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
40. Sevlever D., Jiang P., Yen S.H. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 2008, 47:9678-9687.
41. Smith W.W., Margolis R.L., Li X., Troncoso J.C., Lee M.K., Dawson V.L., Dawson T.M., Iwatsubo T., Ross C.A. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 2005, 25:5544-5552.
42. Takahashi M., Ko L.W., Kulathingal J., Jiang P., Sevlever D., Yen S.H. Oxidative stress-induced phosphorylation, degradation and aggregation of alpha-synuclein are linked to upregulated CK2 and cathepsin D. Eur. J. Neurosci. 2007, 26:863-874.
43. Tofaris G.K., Spillantini M.G. Physiological and pathological properties of alpha-synuclein. Cell. Mol. Life Sci. 2007, 64:2194-2201.
44. Ulusoy A., Febbraro F., Jensen P.H., Kirik D., Romero-Ramos M. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur. J. Neurosci. 2010, 32:409-422.
45. Volles M.J., Lansbury P.T. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003, 42:7871-7878.
46. Wakabayashi K., Tanji K., Mori F., Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007, 27:494-506.
47. Wakamatsu M., Ishii A., Iwata S., Sakagami J., Ukai Y., Ono M., Kanbe D., Muramatsu S., Kobayashi K., Iwatsubo T., Yoshimoto M. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging 2008, 29:574-585.
48. West M.J. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 1999, 22:51-61.
49. Xu L., Daly T., Gao C., Flotte T.R., Song S., Byrne B.J., Sands M.S., Parker Ponder K. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum. Gene Ther. 2001, 12:563-573.
50. Yamin G., Uversky V.N., Fink A.L. Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett. 2003, 542:147-152.
51. Yu Z., Xu X., Xiang Z., Zhou J., Zhang Z., Hu C., He C. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS One 2010, 5:e9956.
52. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., Summerford C., Samulski R.J., Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999, 6:973-985.